Drug intelligence / Profile preview

TAA6

Development stage: Unknown
Lead developer: PersonGen BioTherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

TAA6 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. It is designed to treat patients with relapsed/refractory Acute Myeloid Leukemia (AML) that expresses the CD276 antigen. The therapy involves genetically modifying a patient's own T cells to express a chimeric antigen receptor that specifically targets CD276, enabling these modified T cells to recognize and eliminate CD276-positive cancer cells.

Other names: TAA6 cell injectionTAA-6 cell injectionTAA 6 cell injection

Targets

B7-H3

Beyond the preview

Go deeper on TAA6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAA6.

Explore the full profile